Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study
To the Editor: Apremilast is an oral phosphodiesterase-4 inhibitor with a 33% efficacy of achieving Psoriasis Area and Severity Improvement (PASI) 75 at 16 weeks for patients with moderate to severe plaque psoriasis.1 Common adverse effects include gastrointestinal symptoms, headache, and nasopharyngitis.1 Clobetasol propi onate spray 0.05%, a clobetasol formulation with similar efficacy and potency to other topical clobetasol preparations, is effective at achieving rapid PASI 75 reduction at 4 weeks but cannot be used long-term because of potential skin and adrenal adverse effects.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Chapman Wei, Adam J. Friedman, Ronald B. Prussick Tags: Letter Source Type: research
More News: Academies | Clobetasol | Common Cold | Dermatology | Gastroenterology | Headache | Migraine | Psoriasis | Skin | Study